Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report
Real-time Estimate Quote. Real-time Estimate Tradegate - 07/06 01:32:02 am
67.595 EUR   +1.37%
07/02BAYER AG : Warburg Research remains Neutral
MD
07/01BAYER AG : Bernstein gives a Buy rating
MD
07/01BAYER AG : JP Morgan reiterates its Neutral rating
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bayer says it makes progress in settlement talks over weedkiller

share with twitter share with LinkedIn share with facebook
05/25/2020 | 04:43am EDT
Logo of Bayer AG at a plant of the German pharmaceutical and chemical maker in Wuppertal

By Ludwig Burger

Bayer said on Monday it had made progress seeking a settlement over claims its glyphosate-based Roundup weedkiller causes cancer, after Bloomberg reported the company reached a verbal agreement on about 50,000 to 85,000 cases.

The drugs and pesticides group is keen to draw a line under the legal dispute, which it inherited via its $63 billion (£52 billion) takeover of Monsanto in 2018. In April, Bayer's management regained shareholder support for its handling of the litigation process.

Bloomberg cited people familiar with the negotiations as saying that the deals have yet to be signed and Bayer is likely to announce the settlements in June.

"We've made progress in the Roundup mediation discussions under the auspices of Ken Feinberg, but in keeping with the confidentiality of this process, the company will not speculate about settlement outcomes or timing," a Bayer spokesman said, referring to a court-appointed mediator.

Bayer's shares rose 4.8% to 60.41 euros at 0734 GMT, recouping losses over the previous three trading sessions.

Bloomberg reported the overall number of U.S. cancer lawsuits stood at 125,000, including tens of thousands being held in abeyance by plaintiffs' lawyers under agreements with Bayer.

Bayer said in April it has been served with cases in court from 52,500 U.S. plaintiffs who blame Roundup and other glyphosate-based weedkillers for their cancer, up from 48,600 in February.

The Bayer spokesman said potential plaintiffs with unserved cases accounted for the difference but he said the company expected more claims to be filed in court because lawyers have advertised heavily to recruit plaintiffs.

"For several reasons, many claims gathered by lawyers will not be compensable in a settlement programme," he added.

Bloomberg reported the verbal agreements were part of a prospective $10 billion deal package, which would include $2 billion for any future cases that are brought after the deal.

Bayer said in February that the average analyst prediction of a settlement was for about $10 billion and that Bayer would not have to write down the value of the Monsanto acquisition in case of such a deal with plaintiffs.

Bloomberg said that under terms of the prospective deals, Roundup would continue to be sold in the United States and plaintiffs' attorneys would agree to stop taking new cases or advertising for new clients.

(Reporting by Ludwig Burger; editing by Thomas Seythal and Jane Merriman)

Stocks mentioned in the article
ChangeLast1st jan.
AT HOME GROUP INC. 3.91% 6.64 Delayed Quote.20.73%
BAYER AG -0.60% 66.68 Delayed Quote.-8.42%
JUST GROUP PLC -4.49% 48.9 Delayed Quote.-38.10%
THE NEW HOME COMPANY INC. 0.63% 3.2 Delayed Quote.-31.33%
WILL GROUP, INC. 0.32% 636 End-of-day quote.-49.20%
share with twitter share with LinkedIn share with facebook
Latest news on BAYER AG
07/02BAYER AG : Warburg Research remains Neutral
MD
07/01BAYER AG : Bernstein gives a Buy rating
MD
07/01BAYER AG : JP Morgan reiterates its Neutral rating
MD
07/01BAYER AG : Buy rating from UBS
MD
06/26BAYER AG : Warburg Research gives a Neutral rating
MD
06/26BAYER AG : Deutsche Bank gives a Buy rating
MD
06/26BAYER AG : Gets a Neutral rating from Independant Research
MD
06/25BAYER AG : Kepler Chevreux remains Neutral
MD
06/25BAYER BETS ON SCIENCE IN BID TO PREV : legal experts
RE
06/25EUROPE : European stocks end higher as mood improves, Lufthansa jumps
RE
More news
Financials
Sales 2020 44 324 M 49 856 M 49 856 M
Net income 2020 4 512 M 5 075 M 5 075 M
Net Debt 2020 29 997 M 33 741 M 33 741 M
P/E ratio 2020 14,4x
Yield 2020 4,38%
Capitalization 65 508 M 73 646 M 73 683 M
EV / Sales 2019
EV / Sales 2020 2,15x
Nbr of Employees 102 201
Free-Float 100,0%
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 82,52 €
Last Close Price 66,68 €
Spread / Highest target 65,0%
Spread / Average Target 23,8%
Spread / Lowest Target -59,6%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Norbert Winkeljohann Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Bijoy Sagar Chief Information Technology Officer
Paul Achleitner Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG-8.42%73 646
JOHNSON & JOHNSON-3.36%371 399
ROCHE HOLDING AG4.71%295 898
MERCK & CO., INC.-13.38%198 849
NOVARTIS AG-10.36%192 057
PFIZER, INC.-11.92%191 697